The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
AbbVie’s hepatitis C treatment Maviret (glecaprevir + pibrentasvir) was on a roll in FY2018, joining the top 10 drug list in Japan - with sales to the tune of 117.7 billion yen - to sit along with familiar faces like…
To read the full story
Related Article
- Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
- Keytruda Keeps Top Drug Crown in FY2020 despite Double-Digit Dip: Tally
July 28, 2021
- Keytruda Logs 64% Growth, Tops FY2019 Drug Ranking: Jiho Tally
June 19, 2020
- No Drug Breaks 100 Billion Yen Mark in FY2017 Japan Sales Ranking: Jiho Tally
July 6, 2018
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…